Pharming Lowers FY2026 Sales Guidance from $405.000M-$425.000M to $375.000M-$395.000M vs $419.100M Est
Benzinga Newsdesk 3 months ago
NewsGuidance
Pharming (NASDAQ:PHAR) lowers FY2026 sales outlook from $405.000 million-$425.000 million to $375.000 million-$395.000 million vs $419.100 million estimate.
Pharming (NASDAQ:PHAR) lowers FY2026 sales outlook from $405.000 million-$425.000 million to $375.000 million-$395.000 million vs $419.100 million estimate.